Simple methods for the rapid exchange of flow cytometric data between remote centers

Lorenzana, R.; Coustan‐Smith, Elaine; Antillón, Federico; Ribeiro, Raul C.; Campana, Dario

doi:10.1038/sj.leu.2401612

Cited by 19 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Continued training of study group members was pursued to support the standardization process, i.e., (i) Rotational personnel exchange (multiple day site visits), (ii) Twice-yearly entire group workshops with written summary reports, (iii) Joint list-mode data (LMD) file reviewing during workshops or online via FTP-server (access limited to group members) (21). LMD files could be exchanged between BC and BD software and , but these can undoubtedly be added to the leukemic cluster.…”

Section: Materials and Methods Standardized Flow Cytometrymentioning

confidence: 99%

Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible

Dworzak

Gaipa

Ratei

et al. 2008

Cytometry Part B Clinical

142

146

View full text Add to dashboard Cite

show abstract

Section: Materials and Methods Standardized Flow Cytometrymentioning

confidence: 99%

Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible

Dworzak

Gaipa

Ratei

et al. 2008

Cytometry Part B Clinical

142

146

View full text Add to dashboard Cite

show abstract

“…Finally, the simultaneous analysis of several parameters can also help to determine with greater accuracy the presence of functionally important cell subsets, such as those with "stem cell" features (32). These advantages notwithstanding, several studies demonstrated that MRD monitored by four-color FCM can still be clinically informative (11,37,38).PFC may introduce the potential for technical problems. For example, setting up multicolor FCM for MRD analysis is not simply achieved by adding new reagents to existing panels but requires careful testing, validation, and quality control (26,39,40).…”

mentioning

confidence: 99%

Detection of minimal residual disease in pediatric acute lymphoblastic leukemia

Gaipa

Basso

Biondi

et al. 2013

Cytometry Part B Clinical

View full text Add to dashboard Cite

Minimal residual disease (MRD) is a powerful predictor of the overall response to treatment in childhood acute lymphoblastic leukemia (ALL). INTRODUCTIONMost children with acute lymphoblastic leukemia (ALL) achieve complete remission with current treatment regimens but leukemia relapse, the main cause of treatment failure, still occurs in a significant proportion of patients (1). Periodic assessment of treatment response provides an indication of the sensitivity of leukemic cells to chemotherapy and of the overall treatment effectiveness. Historically, treatment response has been monitored by morphological examination of bone marrow aspirates, a task which is a fundamental component of the clinical care of patients with ALL (2). Because this approach has a limited sensitivity and specificity, it can result in failure to detect residual leukemic cells, potentially leading to under-treatment and an increase risk of relapse. Conversely, misclassification of normal cells as ALL blasts may result in over-treatment and an increase in the risk of treatment-related morbidity.Over the last 2-3 decades, much effort has been made to develop accurate and sensitive methods that could determine response to treatment more precisely than morphology, and to detect residual leukemia persisting in patients considered to be in morphologic remission, i.e. minimal residual disease (MRD) (3,4). Many studies have demonstrated that MRD is a powerful predictor of clinical outcome in childhood ALL (5-12), supporting the use of a more stringent definition of hematological remission based on MRD assays rather than morphology (13). METHODOLOGIES FOR MRD DETECTIONTo be informative, MRD assays for ALL should allow to the detection of one leukemic cell among 10,000 normal cells or more. They should also reliably discriminate leukemic and normal cells, and allow a timely output of (14)(15)(16)(17)(18). Currently, the most reliable methods to study MRD in ALL are flow cytometric (FCM) analysis of leukemia-associated immunophenotypes (i.e., aberrant phenotypes expressed in leukemic cells but not in normal bone marrow or peripheral blood cells), and polymerase chain reaction (PCR) amplification of antigen receptor gene rearrangements (2,14-23); gene fusion transcripts can also be used as PCR targets in some cases (24). The main features of these techniques are outlined in Table 1. A BRIEF HISTORY OF THE DEVELOPMENT OF MULTICOLORFLOW CYTOMETRY IMMUNOPHENOTYPING Antigen expression is assessed by quantification of the signal emitted by fluorochrome-conjugated-specific monoclonal antibodies (MoAb). Fluorescein excited by an argon laser was initially used in the Herzenberg laboratory, followed by two-color fluorescence detection (25).Then, additional antibody-conjugated fluorochromes were developed to increase the number of "colors" (26). From the 1980s, the capacity of several molecules to absorb and transfer energy to other fluorescent molecules was exploited to produce tandem dyes such as PETexas Red, PE-Cy5, PE Cy7, and Alexa (27,28), thus many la...

show abstract

“…Web-based consultation with SJCRH, as described previously, facilitated quality control. 10 A total of 1148 diagnostic specimens (1089 bone marrow, 59 blood) from 1118 patients were analyzed. Of these, 30 were recollected to replace specimens that could not be evaluated because of nonviable cells due to delayed shipping or processing (n ¼ 11), bacterial contamination (n ¼ 3), dilution of bone marrow with blood (n ¼ 6), or inconclusive findings (n ¼ 10).…”

mentioning

confidence: 99%

“…Ongoing training and quality assurance were accomplished by our innovative use of a webbased system for rapid exchange of flow cytometric data between centers, which proved highly effective. 10 Importantly, in the fifth year of the program, after analysis of hundreds of cases, the reference laboratory rarely required consultation with SJCRH (3% of cases) and the consultations refined or altered the diagnosis in only 1% of all cases (two of eight consulted cases). We consider this program to be a paradigm of technology transfer from developed countries to those with limited resources in a way that builds local capacity and fosters independence -characteristics essential for sustainable development.…”

mentioning

confidence: 99%

Development of a regional flow cytometry center for diagnosis of childhood leukemia in Central America

et al. 2005

Self Cite

View full text Add to dashboard Cite

Simple methods for the rapid exchange of flow cytometric data between remote centers

Cited by 19 publications

References 6 publications

Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible

Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible

Detection of minimal residual disease in pediatric acute lymphoblastic leukemia

Development of a regional flow cytometry center for diagnosis of childhood leukemia in Central America

Contact Info

Product

Resources

About